Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation TCT 2025

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

Presenter: Hisao Otsuki

October 26, 2025

Presentation TCT 2024

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 28, 2024

Presentation TCT 2019

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

Presenter: William Fearon

September 27, 2019

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation EuroPCR 2018

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

Presenter: Panagiotis Xaplanteris

May 23, 2018

Presentation CIT 2018

The study is presented on behalf of the FAME 2 Investigators

Presenter: William F. Fearon

March 23, 2018

Presentation TCT 2017

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, William F. Fearon

November 02, 2017

Presentation Stanford Coronary Physiology Conference 2016

FFR-Guided PCI Vs Medical Therapy: FAME 2 and Substudies

Presenter: Bernard De Bruyne

October 28, 2016

Presentation TCT 2015

Physiological Assessment in Multivessel Disease: What Will SYNTAX 2 and FAME 3 Tell Us?

Presenter: Sergio B Baptista, Eric Van Belle, Bernard De Bruyne

October 12, 2015

Presentation TCT 2015

Fifteen-Year DEFER and 5-Year FAME Outcomes

Presenter: Allen Jeremias, Nils Johnson, Nico H.J. Pijls

October 12, 2015

Presentation Physiology and Intravascular Imaging 2014

FAME 1 and FAME 2: What Is the Evidence for the Use of FFR to Guide Clinical Decision Making?

Presenter: William F. Fearon

March 28, 2014

Presentation TCT 2013

FAME 2: Essential results

Presenter: William Fearon

October 27, 2013

Presentation TCT 2012

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

Presenter: William Fearon

October 24, 2012

Advertisement

TCT 216: Outcomes based on the completeness of revascularization in patients with three-vessel coronary artery disease: The FAME 3 Trial

TCT 23: Outcomes After FFR-Guided PCI Compared With CABG in Patients Presenting With Acute Coronary Syndrome: A Pre-Specified Subgroup Analysis of the FAME 3 Trial

The Case for Functional (Not Anatomic) Complete Revascularization: Preview of FAME 3

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Five-year Outcomes with PCI Guided by Fractional Flow Reserve in Patients with Stable Coronary Artery Disease (FAME 2)

The study is presented on behalf of the FAME 2 Investigators

FAME 2: 3-Year Clinical and Cost-effectiveness Outcomes of FFR-Guided PCI in Patients With Coronary Artery Disease

FFR-Guided PCI Vs Medical Therapy: FAME 2 and Substudies

Physiological Assessment in Multivessel Disease: What Will SYNTAX 2 and FAME 3 Tell Us?

Fifteen-Year DEFER and 5-Year FAME Outcomes

FAME 1 and FAME 2: What Is the Evidence for the Use of FFR to Guide Clinical Decision Making?

FAME 2: Essential results

FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content